Head-To-Head Contrast: Soleno Therapeutics (NASDAQ:SLNO) versus Xeris Biopharma (NASDAQ:XERS)

Xeris Biopharma (NASDAQ:XERS) and Soleno Therapeutics (NASDAQ:SLNO) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, valuation, risk and profitability.

Profitability

This table compares Xeris Biopharma and Soleno Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Xeris Biopharma	-5.88%	N/A	-4.66%
Soleno Therapeutics	N/A	-25.88%	-19.84%

Insider & Institutional Ownership

42.8% of Xeris Biopharma shares are held by institutional investors. Comparatively, 97.4% of Soleno Therapeutics shares are held by institutional investors. 4.6% of Xeris Biopharma shares are held by company insiders. Comparatively, 6.4% of Soleno Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Xeris Biopharma and Soleno Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xeris Biopharma	1	2	6	0	2.56
Soleno Therapeutics	1	0	12	2	3.00

Xeris Biopharma currently has a consensus price target of $9.50, indicating a potential upside of 27.01%. Soleno Therapeutics has a consensus price target of $110.62, indicating a potential upside of 158.39%. Given Soleno Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Soleno Therapeutics is more favorable than Xeris Biopharma.

Volatility and Risk

Xeris Biopharma has a beta of 0.5, suggesting that its share price is 50% less volatile than the S&P 500. Comparatively, Soleno Therapeutics has a beta of -3.12, suggesting that its share price is 412% less volatile than the S&P 500.

Valuation and Earnings

This table compares Xeris Biopharma and Soleno Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xeris Biopharma	$203.07 million	6.11	-$54.84 million	($0.10)	-74.80
Soleno Therapeutics	N/A	N/A	-$175.85 million	($1.84)	-23.27

Xeris Biopharma has higher revenue and earnings than Soleno Therapeutics. Xeris Biopharma is trading at a lower price-to-earnings ratio than Soleno Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Soleno Therapeutics beats Xeris Biopharma on 7 of the 13 factors compared between the two stocks.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

About Soleno Therapeutics

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.